HomeABBV34 • BVMF
add
Abbvie Inc BDR
Nakaraang pagsara
R$67.60
Sakop ng araw
R$65.80 - R$68.18
Sakop ng taon
R$40.77 - R$74.95
Market cap
316.04B USD
Average na Volume
1.98K
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 14.46B | 3.83% |
Gastos sa pagpapatakbo | 6.07B | 21.67% |
Net na kita | 1.56B | -12.20% |
Net profit margin | 10.80 | -15.43% |
Kita sa bawat share | 3.00 | 1.69% |
EBITDA | 6.26B | -8.02% |
Aktuwal na % ng binabayarang buwis | 24.95% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 7.28B | -45.18% |
Kabuuang asset | 143.42B | 5.29% |
Kabuuang sagutin | 137.35B | 10.68% |
Kabuuang equity | 6.07B | — |
Natitirang share | 1.77B | — |
Presyo para makapag-book | 19.82 | — |
Return on assets | 7.33% | — |
Return on capital | 13.48% | — |
Cash Flow
Net change in cash
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 1.56B | -12.20% |
Cash mula sa mga operasyon | 5.45B | -28.08% |
Cash mula sa pag-invest | -8.26B | -2,137.40% |
Cash mula sa financing | -3.07B | -15.45% |
Net change in cash | -5.87B | -229.70% |
Malayang cash flow | 5.50B | -26.01% |
Tungkol
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira, administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
It developed Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases. Its other major products include Botox, Imbruvica to treat cancer, Rinvoq to treat arthritis, Venclexta to treat leukemia and lymphoma, Vraylar to treat schizophrenia and bipolar disorder, and Mavyret to treat Hepatitis C. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.
In 2023, Humira began facing competition from a biosimilar developed by Amgen. Wikipedia
Itinatag
Ene 1, 2013
Headquarters
Website
Mga Empleyado
50,000
